sabato, 2 luglio 2022
13 Ottobre 2017

New AML Drugs Approved and Under Investigation in 2017

October 9, 2017 – After nearly 40 years with little in the way of drug development for the treatment of acute myeloid leukemia (AML), four new drugs have been approved by the US Food and Drug Administration (FDA) in 2017 for AML, and several promising agents are in development. Bruno C. Medeiros, MD, a director at the Stanford Comprehensive Cancer Center, in California, discussed the modern landscape of the treatment of AML at the NCCN 12th Annual Congress … (leggi tutto)